SERVING UNMET MEDICAL NEEDS

CannBioRex is developing newly patented compounds in orally active anti-inflammatories in a safe and effective way to fill several major unmet needs within:

PRIMARY TARGETS

Anti-Arthritic Therapy

Osteoarthritis

Chronic and Acute Pain

SECONDARY TARGETS (POST PRIMARY DEVELOPMENTS)

Diabetes

Obesity and Fatty Liver

A HIGHLY EXPERIENCED TEAM

CannBioRex’s Co-Founders Prof Sir Marc Feldmann and Prof Raphael Mechoulam are industry leading scientists who are experts in the development of anti-inflammatory therapeutics and are at the forefront of CannBioRex’s mission to develop safe medicines.

THE BENEFITS OF MEDICAL MARIJUANA PHARMA ARE BEING REALIZED GLOBALLY

The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Marijuana has shown its benefits in multiple suppressive and therapeutic indications. Source: FULD+Company Analyst Report, Market and Competitive landscape for Medical Marijuana and synthetic cannabinoids Source: http://insights.fuld.com/blog/what-medical-marijuana-means-for-pharma-companies